+6 more
Check this report whats the problem in this patient and what recommendations for treatment
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
I now have a thorough picture of all the reports. Let me compile the full analysis.
Patient: Rajendra Mahto, 55 Years, Male
Treating Physician: Dr. Manoj Kumar, MS (ENT) - Shree Sai Hospital, Darbhanga
Problems Identified
1. BILATERAL CONDUCTIVE HEARING LOSS (Primary ENT Problem)
Audiogram findings (09 May 2026):
| Ear | Pure Tone Average (PTA) | Classification |
|---|---|---|
| Right Ear | 60 dBHL | Moderately Severe Conductive Hearing Loss |
| Left Ear | 43.33 dBHL | Moderate Conductive Hearing Loss |
The audiogram shows a clear air-bone gap bilaterally - the bone conduction (BC) thresholds are near normal while air conduction (AC) thresholds are significantly elevated. This is the hallmark of conductive hearing loss, meaning the problem is in the outer/middle ear (not the nerve). This is the reason the patient came to this ENT specialist.
Likely causes in a 55-year-old male:
- Otosclerosis (fixation of the stapes - most common cause of progressive bilateral conductive HL in this age group)
- Chronic otitis media with effusion
- Ossicular chain pathology
2. SUBCLINICAL HYPOTHYROIDISM
Thyroid Profile (06 Apr 2026):
| Test | Result | Normal Range |
|---|---|---|
| Serum T3 | 1.08 ng/ml | 0.79-1.58 (Normal) |
| Serum T4 | 6.65 ug/dl | 4.9-11.0 (Normal) |
| Serum TSH | 7.97 uIU/ml | 0.25-5.0 (HIGH) |
Impression on report: "Subclinical Hypothyroidism" - TSH is elevated (>7.0) but T3 and T4 are still normal. This is relevant because hypothyroidism can worsen hearing loss (myxedematous deposits in the middle ear and cochlea are a known mechanism).
3. PREDIABETES / EARLY TYPE 2 DIABETES
Blood Sugar (06 Apr 2026):
| Test | Result | Normal |
|---|---|---|
| Fasting Blood Sugar | 136 mg% (ELEVATED) | 70-100 mg% |
| Post-Prandial (PP) Sugar | 242 mg% (ELEVATED) | <140 mg% |
| HbA1c | 6.2% | Normal: 4.0-6.0%; Pre-diabetic: 6.1-6.5% |
| Urine Sugar (PP) | PRESENT (+++) | Negative |
The urine also showed glucosuria (sugar in urine). HbA1c of 6.2% places him in the pre-diabetic/impaired glucose tolerance range, but the fasting sugar of 136 and PP sugar of 242 are consistent with Type 2 Diabetes by ADA criteria (fasting ≥126, or PP ≥200). SGPT is mildly elevated at 49 (normal up to 42), which may reflect early non-alcoholic fatty liver changes from insulin resistance.
4. IRON DEFICIENCY ANEMIA (Mild)
Haematology (06 Apr 2026):
| Test | Result | Normal |
|---|---|---|
| Haemoglobin | 10.1 g/dL | Min 12.9 g/dL (male) |
| MCV | 83.7 fL | 80-96 (low-normal) |
| MCH | 24.2 pg | 27.5-33.2 (LOW) |
| MCHC | 28.9% | 33.4-35.5% (LOW) |
| RDW | 20.8 | >13.6 (HIGH) |
| ESR | 42 mm/hr | >15 mm/hr (raised) |
Peripheral blood smear: Anisocytosis (++)
Impression: "Iron Deficiency - Trace" - microcytic hypochromic picture with high RDW pointing to iron deficiency anemia.
5. VIRAL SEROLOGY (Pre-operative Screening) - All Negative
| Test | Result |
|---|---|
| HIV 1&2 | NEGATIVE |
| HBsAg (Hepatitis B) | NEGATIVE |
| HCV (Hepatitis C) | NEGATIVE |
These were ordered as pre-surgical clearance (likely before planned ear surgery). All clear.
Treatment Recommendations
For Conductive Hearing Loss:
- Surgical option (primary): Stapedectomy / Tympanoplasty / Ossiculoplasty depending on the underlying cause. The ENT specialist Dr. Manoj Kumar's hospital offers endoscopic and laser micro-surgery - these are appropriate for this patient. As noted in Harrison's Principles, "microotologic surgery designed to mobilize or replace the stapes... significant improvement in hearing can now be expected."
- Conservative option: A properly fitted hearing aid can provide significant benefit, especially for the left ear (43 dBHL) while the worse right ear (60 dBHL) is surgically evaluated.
- Pre-operatively: Correct anemia and optimize diabetes before any surgery.
For Subclinical Hypothyroidism (TSH 7.97):
- Per Harrison's 22nd Edition: For TSH >7 in a middle-aged symptomatic patient, start Levothyroxine (LT4) at 25-50 mcg/day, titrate to normalize TSH over 2-3 months.
- Treating hypothyroidism is especially relevant here because it can independently contribute to hearing loss.
- The doctor appears to have started a medication that looks like it could be Levothyroxine (one of the 5 prescriptions).
For Diabetes/Pre-diabetes:
- Lifestyle modification: Dietary restriction of carbohydrates, weight management, regular exercise (30 min/day).
- Pharmacotherapy: Given fasting 136 + PP 242 + urine sugar +++, strong consideration for Metformin (500 mg twice daily with meals) as first-line, along with monitoring of HbA1c every 3 months.
- Repeat HbA1c and fasting sugar in 3 months.
For Iron Deficiency Anemia:
- Oral iron supplementation: Ferrous sulfate 200 mg (elemental iron ~60 mg) twice daily for 3 months.
- One of the prescribed tablets appears to be an iron supplement (possibly the "Feleee" or similar that the doctor wrote).
- Recheck CBC and serum ferritin after 8-12 weeks.
- Investigate the source of iron loss (GI evaluation if no dietary cause found).
General Pre-Surgical Optimization:
Since the patient is being evaluated for possible ear surgery, all three systemic issues (anemia, diabetes, hypothyroidism) should be optimized before any elective surgery to reduce perioperative risk.
Summary Table
| Problem | Severity | Priority Action |
|---|---|---|
| Bilateral Conductive HL (R: 60 dB, L: 43 dB) | Moderate-Severe | ENT surgery evaluation / Hearing aid |
| Subclinical Hypothyroidism (TSH 7.97) | Mild-Moderate | Start Levothyroxine 25-50 mcg/day |
| Type 2 Diabetes (FBS 136, PPBS 242) | Moderate | Metformin + lifestyle changes |
| Iron Deficiency Anemia (Hb 10.1) | Mild | Oral iron supplementation x 3 months |
| Pre-op viral screen | Clear | No action needed |
Disclaimer: This analysis is for informational/educational purposes. All treatment decisions must be made by the treating physician (Dr. Manoj Kumar and team) based on full clinical examination of the patient. Do not alter any prescribed medications without consulting the doctor.
Rabeprazole sodium and domperidone
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Here is a complete breakdown of this combination, which is one of the most commonly prescribed gastric combinations in South Asia.
Rabeprazole Sodium + Domperidone
This is a fixed-dose combination (FDC) sold under brand names like Razo-D, Rablet-D, Domstal-RD, etc. The two drugs work on different but complementary mechanisms to relieve upper GI symptoms.
Drug 1: Rabeprazole Sodium
Class
Proton Pump Inhibitor (PPI) - 2nd generation
Mechanism of Action
Rabeprazole is a benzimidazole prodrug. After absorption, it is activated in the acidic environment of the stomach's parietal cells, where it irreversibly binds to and inhibits the H⁺/K⁺-ATPase enzyme (the "proton pump") on the secretory surface of gastric parietal cells. This blocks the final step of acid secretion regardless of the stimulus (histamine, gastrin, or acetylcholine).
Rabeprazole has a faster onset than omeprazole/lansoprazole because it has a higher pKa (5.0), so it activates more readily at higher pH levels.
Indications
| Condition | Details |
|---|---|
| GERD (Acid Reflux) | First-line treatment |
| Peptic ulcer disease (gastric/duodenal) | Heals ulcers in 4-8 weeks |
| H. pylori eradication | Part of triple/quadruple therapy |
| Zollinger-Ellison syndrome | High-dose PPI needed |
| NSAID-induced ulcers | Prevention and treatment |
| Dyspepsia | Symptomatic relief |
Dose
- Standard: 20 mg once daily, before breakfast
- Can be given twice daily for severe GERD or ZE syndrome
- Available as: 10 mg, 20 mg tablets (enteric-coated)
Side Effects
- Common: headache, diarrhea, nausea, abdominal pain
- Long-term use: hypomagnesemia, vitamin B12 deficiency, increased risk of C. difficile infection, reduced calcium absorption (fracture risk)
- Rare: interstitial nephritis, hepatotoxicity
Drug 2: Domperidone
Class
Peripheral Dopamine D2 receptor antagonist / Prokinetic + Antiemetic
Mechanism of Action
Domperidone blocks D2 receptors in the:
- Gastric antrum and duodenum - increases gastric motility, speeds gastric emptying, coordinates antroduodenal contractions
- Chemoreceptor trigger zone (CTZ) in the area postrema - this area lies outside the blood-brain barrier, so domperidone can act there without significant CNS penetration
Unlike metoclopramide, domperidone does NOT cross the blood-brain barrier well, so it has far fewer extrapyramidal/CNS side effects.
As noted in Sleisenger & Fordtran's GI textbook: "Domperidone is a dopamine antagonist that decreases nausea, corrects gastric dysrhythmias, and increases gastric emptying rates."
Indications
| Condition | Details |
|---|---|
| Nausea and vomiting | Functional, post-operative, drug-induced |
| Gastroparesis | Especially diabetic gastroparesis (relevant here - this patient has diabetes) |
| Bloating, fullness, belching | Functional dyspepsia |
| GERD adjunct | Improves lower esophageal sphincter tone |
Dose
- 10 mg three times daily, 15-30 minutes before meals
- Maximum: 30 mg/day
- Use the lowest effective dose for the shortest duration
Side Effects
- QT prolongation - the most important safety concern; can rarely cause serious arrhythmias (avoid with other QT-prolonging drugs)
- Hyperprolactinemia (galactorrhea, gynecomastia, menstrual irregularities)
- Dry mouth, headache
- Minimal extrapyramidal effects (unlike metoclopramide)
As Fischer's Mastery of Surgery notes: "Domperidone is a dopamine receptor antagonist like metoclopramide but has a lower incidence of central side effects. However, it has a higher incidence of QT prolongation."
Why These Two Are Combined
| Problem | Drug That Addresses It |
|---|---|
| Excess acid production | Rabeprazole (reduces acid at source) |
| Slow gastric emptying / reflux of contents | Domperidone (speeds stomach emptying) |
| Nausea / bloating | Domperidone (antiemetic + prokinetic) |
| Esophageal mucosal damage | Rabeprazole (creates less acid to damage mucosa) |
The combination tackles both the acid component AND the motility component of GERD/dyspepsia simultaneously, which is why it is so widely prescribed.
Relevance to This Patient (Rajendra Mahto)
This combination is likely prescribed here because:
- The patient has diabetes - diabetic patients commonly develop gastroparesis (delayed gastric emptying) causing bloating, nausea, fullness
- He is likely going on iron supplements and Levothyroxine, both of which can cause gastric irritation and need gastroprotection
- Pre-surgical patients benefit from acid suppression
Important Cautions for This Patient Specifically
- QT monitoring - domperidone can prolong QT; baseline ECG is advisable
- Drug interaction - domperidone should not be combined with azithromycin, fluconazole, or other QT-prolonging agents
- Duration - PPIs should not be taken indefinitely without reassessment; typically 4-8 weeks for acute conditions
- Take rabeprazole before meals (30 min before breakfast) for best acid suppression
- Take domperidone before meals (15-30 min before) for best prokinetic effect
All medication decisions remain with the treating physician. Do not start, stop, or modify doses without medical consultation.
This is a shared conversation. Sign in to Orris to start your own chat.